"With this technology and the team that developed it now part of Agilent, we can expand our reach in the pharmaceutical and clinical mass spec markets," an Agilent official said of the Biocius purchase.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.